8039 — TAIFLEX Scientific Co Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD9.83bn
- TWD10.68bn
- TWD8.15bn
- 53
- 40
- 65
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 792 | 966 | 941 | 877 | 482 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 30.6 | 44.7 | 84.6 | 185 | 94.7 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 821 | -212 | -1,194 | -352 | 236 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,994 | 1,133 | 228 | 1,142 | 1,272 |
Capital Expenditures | -788 | -551 | -529 | -977 | -1,015 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -70.5 | 348 | -543 | 289 | 30.5 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -858 | -203 | -1,072 | -688 | -985 |
Financing Cash Flow Items | 216 | -216 | 19.8 | 4.44 | 15.7 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -359 | -1,723 | 2,306 | -1,512 | -568 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 722 | -791 | 1,477 | -1,006 | -299 |